X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ROME intends to use the funds to advance its drug candidate, RPT-2950, an inhibitor of LINE-1 reverse transcriptase (RT), through early clinical trials, including Phase 1 studies to evaluate safety and determine optimal dose, and further advancement of pipeline and platform.
Lead Product(s): RPT-2950
Therapeutic Area: Immunology Product Name: RPT-2950
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $149.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 12, 2023
Details:
ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sanofi Ventures
Deal Size: $77.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 14, 2021
Details:
The capital would help in clinical advancement of several promising drug targets identified by ROME and may boost launch of multiple discovery programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
